All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...

CERo Therapeutics (CERO) announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share.

Shattuck stock plunges as it discontinues the clinical development of SL-172154 for two blood cancer indications ... in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk ...

Two posters presented at the 2024 American ... A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce toxicity, according ...

Under the direction of Dr. Guru Subramanian Guru Murthy at the Medical College of Wisconsin Cancer Center, the trial ( NCT06502145) will evaluate the safety, tolerability, and recommended Phase II ...

Immune cells in the bone marrow microenvironment of AML patients are key in distinguishing a response to immunotherapy.

Inhibiting RSK1 eliminated up to 96% of cancer in mice after four weeks. It also showed evidence of preventing the chronic disease from transforming into secondary AML. In the Blood Cancer Journal ...

increasing the potential of cancer relapse. Dr. Orvain and his colleagues analyzed data from 1,265 adult patients with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS)/AML who underwent ...

In 2023, we published another article about CRSP in Cell Biology Education – A Journal of Life Science Education. That article assesses the impact of shifting research modalities and their impacts on ...

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have ...